EUVIMEDOpdag EUVIMED
CrossrefInfokort

Trastuzumab: preparation and planning will avoid chaos

Steve Chaplin

Future Prescriber · 2006

DOI: 10.1002/fps.19 ↗
AbstractBibliografiske oplysninger

Abstract

Abstract Trastuzumab has been shown to improve disease‐free, and overall, survival in women with early HER2‐positive breast cancer. It is undergoing rapid appraisal by NICE with the aim of providing prompt guidance for use within the NHS. The DOH has pledged to support its use, yet without increasing PCT funding for support services and additional drug costs. The criteria by which PCTs can decide or decline to pay for treatment remain unclear. Copyright © 2006 John Wiley & Sons, Ltd.

Viden, der passer til dit arbejde.

Fra en gratis start over personlig litteratursøgning til den komplette Research Suite.

Se priser →

Er alle forlagsfuldtekster inkluderet?

Nej. Bibliografiske referencer, abstracts og fuldtekster er forskellige typer indhold. Om en fuldtekst er tilgængelig, afhænger af kilden, Open Access og dine eksisterende licenser. Et EUVIMED-abonnement erstatter ikke yderligere forlagsrettigheder.

Se priser →